Experimental macromolecular aerosol therapy

Respiratory Care

Volumn 45, Issue 6, 2000, Pages 684-694

  Rubin, Bruce K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosol; Airway; Clearance; Cough; Gene transfer; Inflammation; Macromolecule; Mucoactive; Mucociliary; Mucolytic

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CYCLOOXYGENASE 1 INHIBITOR; GLUCOCORTICOID; GLUTATHIONE PEROXIDASE; LEUKOCYTE ELASTASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

AEROSOL; CONFERENCE PAPER; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; HUMAN; MACROMOLECULE; PNEUMONIA; TREATMENT OUTCOME;

AEROSOLS; ANTI-INFLAMMATORY AGENTS; EXPECTORANTS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MACROMOLECULAR SUBSTANCES; PNEUMONIA; RESPIRATORY TRACT DISEASES;

EID: 0033930987     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Gaensslen M Uber inhalation von Insulin Wein Klin. Wochenschr. 1925,2.71-72.
2. Desai MA, Mutlu M, Vadgama P. A study of macromolecular diffusion through native porcine mucus Expenentia 1992;48(1);22-26.
3. Bhat PG, Flanagan DR, Donovan MD, Drug diffusion through cystic fibrotic mucus steady-state permeation, rheologic properties, and glycoprotein morphology. J Pharm Sci 1996;85(6):624-630.
4. Schürch S, Gehr P, Im Hof V, Geiser M, Green F Surfactant displaces particles toward the epithelium in airways and alveoli Respir Physiol 1990;80(1):17-32
5. Kharasch VS, Sweeney TD, Fredberg J, Lehr J, Damokosh AI, Avery ME, Brain JD. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 1991;144(4):909-913
6. Adler KB, Fischer BM, Wright DT, Cohn LA, Becker S Interactions between respiratory epithelial cells und cytokines relationships to lung inflammation (review). Ann NY Acad Sci 1994;725:128-145.
7. Tamaoki J, Chiyotani A, Kobayashi K, Sakai N, Kanemura T, Takizawa T. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis Am Rev Respir Dis 1992;145(3):548-552.
8. Vogelmeier C, Gillissen A, Buhl R. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity (review). Chest 1996;110(6 Suppl):261S-266S
9. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, et al Modulation of airway inflammation in cystic fibrosis, in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90(4):1296-1301.
10. Gillissen A, Birrer P, McElvaney NG, Buhl R, Vogelmeier C, Hoyt RF Jr, et al. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Applied Physiol 1993;75(2):825-32
11. Stolk J, Camps J, Feitsma HI, Hermans J, Dijkman JH, Pauwels EK. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax 1995;50(6):645-50.
12. Wright CD, Havill AM, Middleton SC, Kashem MA, Lee PA, Dripps DJ, et al. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J Pharmacol Exp Ther 1999;289(2):1007-1014.
13. Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract anti-neutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency J Clin Invest 1989;84(4):1349-1354.
14. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337(8738):392-394.
15. Smith RM, Spragg RG. Production and administration to dogs of aerosols of alpha-1-proteinase inhibitor. Am J Med 1988;84(6A): 48-51
16. Lack G, Renz H, Saloga J, Bradley KL, Loader J, Leung DY, et al. Nebulized but not parenteral IFN-gamma decreases IgE production and normalizes airways function in a murine model of allergen sensitization J Immunol 1994;152(5):2546-2554.
17. Martin RJ, Boguniewicz M, Henson JE, Oelniker AC, Williams M, Giorno RC, Leung DY. The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis 1993;148(6 Pt 1):1677-1682
18. Giosue S, Casarini M, Alemanno L, Galluccio G, Mattia P, Pedicelli G. et al. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998;158(4):1156-1162
19. Buhl R, Meyer A, Vogelmeier C. Oxidant-protease interaction in the lung prospects for antioxidant therapy (review). Chest 1996;110 (6 Suppl)267S-272S.
20. Gillissen A, Roum JH, Hoyt RF, Crystal RG. Aerosolization of superoxide dismutase: augmentation of respiratory epithelial lining fluid antioxidant screen by aerosolization of recombinant human Cu - - /Zn + + superoxide dismutase. Chest 1993;104(3):811-815.
21. Hybertson BM, Kitlowski RP, Jepson EK, Repine JE. Supercritical fluid-aerosolized vitamin E pretreatment decreases leak in isolated oxidant-perfused rat lungs. J Appl Physiol 1998;84(1):263-268.
22. Morgenroth K, Bolz J. Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration 1985;47(3):225-231.
23. Rubin BK, Tomkiewicz RP, King M. Mucoactive agents: old and new. In: Wilmott RW, editor. The pediatric lung. Basel, Switzerland: Birkhäuser Publishing; 1997: 155-179.
24. King M, Rubin BK, Mucus rheology: relationship with transport.In: Takishima T, editor. Airway secretion. physiological bases for the control of mucus hypersecretion. New York: Marcel Dekker; 1994: 283-314.
25. King M, Rubin BK. Mucus physiology and pathophysiology: therapeutic aspects. In: Derenne JP, Similowski T, Whitelaw WA, editors. Chronic obstructive lung disease. New York: Marcel Dekker; 1996: 391-411
26. Puchelle E, Zahm JM, Girard F, Bertrand A, Polu JM, Aug F, Sadoul P Mucociliary transport in vivo and in vitro: relations to sputum properties in chrome bronchitis. Eur J Respir Dis 1980;61(5):254-264.
27. Rubin BK, MacLeod PM, Sturgess J, King M. Recurrent respiratory infections m a child with fucosidosis: is the mucus too thin for effective transport? Pediatr Pulmonol 1991;10(4):304-309.
28. Dueholm M, Nielsen C, Thorshauge H, Evald T, Hansen NC, Madsen HD, Maltbaek N. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med 1992;86(2):89-92.
29. Hansen NCG, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994;88(7):531-535.
30. Ventresca GP, Cicchetti, Ferrari V. Acetylcysteine. In: Braga PC, Allegra L, editors. Drugs in bronchial mucology. New York: Raven Press; 1989: 77-102.
31. Tomkiewicz RP, App EM, De Sanctis GT, Coffiner M, Maes P, Rubin BK, King M. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Pulm Pharmacol 1995;8(6):259-265
32. Feng W, Garrett H, Speert DP, King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro Am J Respir Crit Care Med 1998;157(3 Pt 1):710-714.
33. Tomkiewicz RP, Kishioka C, Freeman J, Rubin BK. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G. Cilia, mucus, and mucociliary interactions. New York: Marcel Dekker; 1998: 333-341.
34. Shak S. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis (review). Chest 1995;107(2 Suppl):65S-70S.
35. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331(10):637-642.
36. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113(5):1329-1334.
37. Fiel SB, Fuchs HJ, Johnson C, Gonda I, Clark AR Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group. Chest 1995;308(1):153-156.
38. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease m cystic fibrosis. Respir Med 1995;89(7):499-502.
39. Geller DE, Eigen H, Fiel SB, Clark A, Lamarre AP, Johnson CA, Konstan MW. Effect of smaller droplet sizce of domase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Pediatr Pulmonol 1998;25(2):83-87.
40. Cipolla DC, Clark AR, Chan H-K, Gonja I, Shire S J. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease: STP Pharma Sci 1994;4:50-62.
41. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994;263(5149):969-971.
42. Rubin BK, Kater AP, Dian T, Ramirez OE, Tomkiewicz RP, Goldstein AL. Effects of thymosin beta 4 on cystic fibrosis sputum. Pediatr Pulmonol Suppl 1995;12:234.
43. Rubin BK Pharmacologic management of mucus retention based on a taxonomy of mucoactive medications. In: Baum G. Cilia, mucus, and mucociliary interactions. New York: Marcel Dekker: 1988; 383-389.
44. Rubin BK, Kishioka C, van der Schans CP, Dowell A, Fiel S. Mucus and mucoactive therapy in chronic bronchitis. Clin Pulm Med 1998; 5:1-14.
45. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995;333(13):823-831.
46. McDonald RJ, Lukason MJ, Raabe OG, Canfield DR, Burr EA, Kaplan JM, et al Safety of airway gene transfer with Ad2/CFTR2: aerosol administration in the nonhuman primate. Hum Gene Ther 1997;8(4):411-422.
47. Sene C, Bout A, Imler JL, Schultz H, Willemot JM, Hennebel V, et al. Aerosol-mediated delivery of recombinant adenovirus to the airways of nonhuman primates. Hum Gene Ther 1995;6(12): 1587-1593.
48. Bellon G, Michel-Calemard L, Thouvenot D, Jagneauv V, Poitevin F, Malcus C, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients' a phase I clinical trial. Hum Gene Ther 1997;8(1):15-25.
49. Flotte TR, Carter BJ. In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis (review). Adv Pharmacol 1997;40: 85-101.
50. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272(5259):263-267.
51. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4(3):199-209.
52. Eastman SJ, Lukason MJ, Tousignant JD, Murray H, Lane MD, St George JA, et al. A concentrated and stable aerosol formulation of cationic lipid: DNA complexes giving high-level gene expression in mouse lung. Hum Gene Ther 1997;8(6):765-773.
53. Pillai R, Petrak K, Blezmger P, Deshpande D, Florack V, Freimark B, et al. Ultrasonic nebulizatton of cationic lipid-based gene delivery systems for airway administration. Pharm Res 1998;15(11):1743-1747.
54. Stern M, Caplen NJ, Browning JE, Griesenbach U, Sorgi F, Huang L, et al. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro Gene Ther 1998;5(1):91-98.
55. Gendler SJ, Spicer AP. Epithelial mucin genes (review) Annu Rev Phvsiol 1995;57:607-634.
56. Rubin BK. Emerging therapies for cystic fibrosis lung disease (review) Chest 1999;115(4):1120-1126.